✓
Open
5 Feb 2025
✓
Close
7 Feb 2025
3
Allotment
—
✓
Listing
Wed, Feb 12, 2025
Price Band
₹105 to ₹111
Issue Size
54,03,600 shares (agg. up to ₹60 Cr)
Lot Size
1,200 Shares
Listing Date
Wed, Feb 12, 2025
Latest GMP
₹0
Est. Gain
0%
✦ AI Insight
GMP Trend
12-02-2025₹0Est. ₹111+0%
11-02-2025₹0Est. ₹111+0%
10-02-2025₹0Est. ₹111+0%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 5.67x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 28.89 | 18.98 | 12.39 | 6.59 |
| Total Income | 23.25 | 44.28 | 30.28 | 27.62 |
| Profit After Tax | 6.52 | 12.54 | 3.11 | 2.57 |
| NET Worth | 23.68 | 17.16 | 4.60 | 1.49 |
| Reserves and Surplus | 8.08 | 17.11 | 4.57 | 1.46 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Sat Kartar Shopping Ltd. | SME | ₹33.80 Cr | ₹81 | 14.87 | ₹161.55 | +99.44% | ₹130.00 (-1.59%) |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹39.55 (+4.91%) |
| Medicamen Organics Ltd. | SME | ₹10.54 Cr | ₹34 | 30.53 | ₹144.70 | +325.59% | ₹23.00 (-1.50%) |
| Quest Laboratories Ltd. | SME | ₹43.16 Cr | ₹97 | 23.03 | ₹147.35 | +51.91% | ₹96.95 (+8.08%) |
| Zenith Drugs Ltd. | SME | ₹40.68 Cr | ₹79 | 18.4 | ₹105.15 | +33.10% | ₹50.10 (-4.48%) |
| Senores Pharmaceuticals Ltd. | Mainboard | ₹582.11 Cr | ₹391 | 39.77 | ₹557.80 | +42.66% | ₹1,452.90 (-1.74%) |
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,294.90 (+2.45%) |
| Akums Drugs & Pharmaceuticals Ltd. | Mainboard | ₹1,856.74 Cr | ₹679 | null | ₹796.25 | +17.27% | ₹682.95 (-1.22%) |
| Emcure Pharmaceuticals Ltd. | Mainboard | ₹1,952.03 Cr | ₹1008 | 34.55 | ₹1,359.15 | +34.84% | ₹1,802.70 (+0.61%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding of Working Capital Requirement of the company | 25.00 |
| 2 | Marketing and brand building activities | 5.00 |
| 3 | General Corporate Purposes | 14.24 |
| 4 | Issue expenses | 5.70 |
| Total | 49.93 |
About Amwill Health Care IPO
Incorporated in August 2017, Amwill Health Care Limited is a derma-cosmetic development firm that collaborates with contract manufacturers, distributors, and third-party product development agencies. This collaboration has enhanced the company's manufacturing, packaging, and distribution capabilities. The product portfolio of the Company is divided into two categories, namely, Development of generic dermatological solutions and Formulating targeted solutions for dermatological issues. The company markets its products in Karnataka, Andhra Pradesh, and Telangana, focusing on strengthening its presence before entering new markets to build a customer base. The company develops products for dermatological disorders, including acne, fungal infections, anti-aging, histaminic, periorbital hyperpigmentation, scabies, perspiration, trichology, and vitiligo. As of September 30, 2024, the company has 84 employees on payroll. Competitive Strength Extensive product portfolio supported by product formulation capabilities Provision of high-quality product development through tie-ups with contract manufacturers and prototype developers Well-experienced management team with proven project management
Contact Details
Amwill Health Care Ltd. AddressNo.157, 1st Floor2nd Main, r, 2nd Main, 3rd Cross ChamrajpetBangalore UrbanBengaluru, Karnataka, 560018+91 8043026281amwill@amwillhealthcare.comVisit Website